Advances in glucocorticoid-induced osteoporosis

Curr Rheumatol Rep. 2011 Jun;13(3):233-40. doi: 10.1007/s11926-011-0173-y.

Abstract

Glucocorticoid-induced osteoporosis (GIOP) is one of the most important side effects of glucocorticoid use, as it leads to an increased risk of fractures. Recently, many published studies have focused on the cellular and molecular mechanisms of bone metabolism, the pathophysiology of GIOP, and the intervention options to prevent GIOP. In this review, recent advances in GIOP are summarized, particularly recent progress in our understanding of the mechanisms of GIOP resulting in improved insight that might result in the development of new treatment options in the near future.

Publication types

  • Review

MeSH terms

  • Bone Density / drug effects
  • Bone and Bones / drug effects
  • Bone and Bones / metabolism
  • Fractures, Spontaneous / chemically induced
  • Fractures, Spontaneous / prevention & control
  • Glucocorticoids / adverse effects*
  • Humans
  • Osteoporosis / chemically induced*
  • Osteoporosis / epidemiology*
  • Osteoporosis / physiopathology
  • Risk Factors

Substances

  • Glucocorticoids